- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03834493
Исследование пембролизумаба (MK-3475) плюс энзалутамид по сравнению с плацебо плюс энзалутамид у участников с метастатическим резистентным к кастрации раком предстательной железы (мКРРПЖ) (MK-3475-641/KEYNOTE-641)
Фаза 3, рандомизированное двойное слепое исследование пембролизумаба (MK-3475) плюс энзалутамид по сравнению с плацебо плюс энзалутамид у участников с метастатическим кастрационно-резистентным раком предстательной железы (мКРРПЖ) (KEYNOTE-641)
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC, are abiraterone-naïve, or are intolerant to or progressed on abiraterone acetate. There are two primary study hypotheses.
Hypothesis 1: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Overall Survival (OS).
Hypothesis 2: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Radiographic Progression-free Survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review.
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
New South Wales
-
Darlinghurst, New South Wales, Австралия, 2010
- St. Vincent's Hospital ( Site 0158)
-
Kogarah, New South Wales, Австралия, 2217
- St George Hospital ( Site 0157)
-
Macquarie University, New South Wales, Австралия, 2109
- Macquarie University ( Site 0151)
-
Port Macquarie, New South Wales, Австралия, 2444
- Port Macquarie Base Hospital ( Site 0153)
-
Waratah, New South Wales, Австралия, 2298
- Calvary Mater Newcastle ( Site 0148)
-
-
Queensland
-
Greenslopes, Queensland, Австралия, 4120
- Gallipoli Medical Research Ltd ( Site 0149)
-
Southport, Queensland, Австралия, 4215
- Gold Coast University Hospital ( Site 0150)
-
-
South Australia
-
Adelaide, South Australia, Австралия, 5000
- Royal Adelaide Hospital ( Site 0154)
-
-
Victoria
-
Clayton, Victoria, Австралия, 3168
- Monash Medical Centre ( Site 0147)
-
-
Western Australia
-
Perth, Western Australia, Австралия, 6150
- Fiona Stanley Hospital ( Site 0162)
-
-
-
-
-
Vienna, Австрия, 1090
- Medizinische Universität Wien ( Site 0375)
-
-
Upper Austria
-
Linz, Upper Austria, Австрия, 4020
- Ordensklinikum Linz GmbH Elisabethinen ( Site 0373)
-
-
-
-
-
Buenos Aires, Аргентина, C1012AAR
- Instituto de Investigaciones Metabolicas [Buenos Aires, Argentina] ( Site 1011)
-
Buenos Aires, Аргентина, C1118AAT
- Hospital Aleman ( Site 1004)
-
Buenos Aires, Аргентина, C1426ABP
- Centro Medico Dra De Salvo ( Site 1018)
-
Córdoba, Аргентина, X5008HHW
- CEMAIC ( Site 1014)
-
La Rioja, Аргентина, F5300COE
- Centro Oncologico Riojano Integral ( Site 1005)
-
Mendoza, Аргентина, M5500AYB
- Centro Oncologico de Integracion Regional. COIR ( Site 1007)
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Аргентина, B1884BBF
- Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)
-
CABA, Buenos Aires, Аргентина, C1015ABO
- Organizacion Medica de Investigacion ( Site 1019)
-
Ciudad Autonoma de Buenos Aires., Buenos Aires, Аргентина, C1426ANZ
- Instituto Medico Alexander Fleming ( Site 1010)
-
Mar del Plata, Buenos Aires, Аргентина, B7600FZO
- Instituto de Investigaciones Clinicas ( Site 1000)
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Аргентина, C1120AAT
- Centro de Diagnostico Urologico ( Site 1008)
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Аргентина, S2000DSV
- Sanatorio Parque ( Site 1002)
-
Rosario, Santa Fe Province, Аргентина, S2000KZE
- Instituto de Oncologia de Rosario ( Site 1015)
-
-
-
-
-
Plovdiv, Болгария, 4000
- MHAT Central Hospital ( Site 0503)
-
Plovdiv, Болгария, 4004
- Complex Cancer Center Plovdiv-First Medical Oncology Department ( Site 0507)
-
-
Sofia (stolitsa)
-
Sofia, Sofia (stolitsa), Болгария, 1301
- MHAT Serdika-Second Department of Medical Oncology ( Site 0505)
-
-
-
-
-
São Paulo, Бразилия, 01509-900
- A.C. Camargo Cancer Center ( Site 1026)
-
São Paulo, Бразилия, 04014-002
- Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 1040)
-
-
Paraná
-
Curitiba, Paraná, Бразилия, 81520-060
- Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1036)
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Бразилия, 59075-740
- Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1032)
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Бразилия, 98700-000
- ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 1038)
-
Porto Alegre, Rio Grande do Sul, Бразилия, 90610-000
- Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1021)
-
-
Santa Catarina
-
Itajaí, Santa Catarina, Бразилия, 88301-215
- Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 1035)
-
-
São Paulo
-
São José do Rio Preto, São Paulo, Бразилия, 15090-000
- Hospital de Base de Sao Jose de Rio Preto ( Site 1022)
-
-
-
-
-
Budapest, Венгрия, 1062
- Magyar Honvedseg Egeszsegugyi Kozpont-Onkologiai Osztaly ( Site 1326)
-
-
Bács-Kiskun county
-
Kecskemét, Bács-Kiskun county, Венгрия, 6000
- Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1321)
-
-
Győr-Moson-Sopron
-
Győr, Győr-Moson-Sopron, Венгрия, 9024
- Petz Aladár Megyei Oktató Kórház-Onkológiai Osztály ( Site 1324)
-
-
Pest County
-
Budapest, Pest County, Венгрия, 1122
- Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 1325)
-
-
-
-
-
Berlin, Германия, 10117
- Charite Universitaetsmedizin Berlin ( Site 0301)
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Германия, 79106
- Universitaetsklinikum Freiburg - Medizinische Klinik ( Site 0304)
-
Nürtingen, Baden-Wurttemberg, Германия, 72622
- Studienpraxis Urologie ( Site 0309)
-
Tübingen, Baden-Wurttemberg, Германия, 72076
- Universitaetsklinik fuer Urologie ( Site 0307)
-
-
Bavaria
-
Munich, Bavaria, Германия, 81675
- Klinikum Rechts der Isar ( Site 0300)
-
Nuremberg, Bavaria, Германия, 90419
- Universitaetsklinik der Paracelsus Medizinischen Privatuniversitaet ( Site 0318)
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Германия, 37075
- Universitaetsklinikum Goettingen ( Site 0345)
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Германия, 52074
- Uniklinik RWTH Aachen ( Site 0308)
-
Münster, North Rhine-Westphalia, Германия, 48149
- Universitaetsklinikum Muenster ( Site 0320)
-
-
Rhineland-Palatinate
-
Trier, Rhineland-Palatinate, Германия, 54292
- Krankenhaus der Barmherzigen Brueder Trier ( Site 0310)
-
-
Saarland
-
Homburg, Saarland, Германия, 66421
- Universitaetsklinikum des Saarlandes ( Site 0348)
-
-
Schleswig-Holstein
-
Lübeck, Schleswig-Holstein, Германия, 23538
- Universitaetsklinikum Schleswig Holstein. ( Site 0346)
-
-
Thuringia
-
Jena, Thuringia, Германия, 07747
- Universitaetsklinikum Jena ( Site 0305)
-
-
-
-
-
Afula, Израиль, 1834111
- HaEmek Medical Center ( Site 0548)
-
Ashdod, Израиль, 7747629
- Assuta Ashdod Medical Center ( Site 0550)
-
Beersheba, Израиль, 8410101
- Soroka Medical Center ( Site 0549)
-
Haifa, Израиль, 3109601
- Rambam Health Care Campus-Oncology Division ( Site 0543)
-
Jerusalem, Израиль, 9112001
- Hadassah Ein Kerem Medical Center ( Site 0546)
-
Kfar Saba, Израиль, 4428164
- Meir Medical Center ( Site 0544)
-
Petah Tikva, Израиль, 4941492
- Rabin Medical Center ( Site 0545)
-
Ramat Gan, Израиль, 5262000
- Chaim Sheba Medical Center ( Site 0541)
-
Tel Aviv, Израиль, 6423906
- Sourasky Medical Center ( Site 0542)
-
Tsrifin, Израиль, 70300
- Yitzhak Shamir Medical Center. ( Site 0547)
-
-
-
-
-
Dublin, Ирландия, D24 NROA
- Tallaght University Hospital ( Site 0730)
-
Dublin, Ирландия, D09 V2N0
- Beaumont Hospital ( Site 0726)
-
Limerick, Ирландия, V98F858
- Mid Western Cancer Centre ( Site 0728)
-
-
-
-
-
Barcelona, Испания, 08003
- Hospital del Mar ( Site 0333)
-
Cáceres, Испания, 10003
- Hospital Provincial San Pedro Alcantara ( Site 0326)
-
Madrid, Испания, 28040
- Hospital Clinico San Carlos ( Site 0324)
-
Madrid, Испания, 28050
- Hospital Universitario HM Sanchinarro ( Site 0322)
-
Madrid, Испания, 28007
- Hospital Universitario Gregorio Maranon ( Site 0327)
-
Madrid, Испания, 28033
- MD Anderson Cancer Center Madrid ( Site 0332)
-
Madrid, Испания, 28223
- Hospital Quiron Madrid ( Site 0325)
-
Málaga, Испания, 29016
- Hospital Universitario Virgen de la Victoria ( Site 0337)
-
Seville, Испания, 41013
- Hospital Virgen del Rocio ( Site 0329)
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Испания, 08908
- Instituto Catalan de Oncologia - ICO ( Site 0330)
-
Sabadell, Barcelona, Испания, 08208
- Hospital Parc Tauli ( Site 0335)
-
-
Gerona
-
Girona, Gerona, Испания, 17007
- Institut Català d'Oncologia (ICO) - Girona ( Site 0321)
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Испания, 46009
- Instituto Valenciano de Oncologia ( Site 0331)
-
-
-
-
-
Arezzo, Италия, 52100
- Medical Oncology Ospedale San Donato ( Site 0461)
-
Bologna, Италия, 40138
- Ospedale Policlinico S. Orsola-Malpighi ( Site 0453)
-
Catania, Италия, 95126
- Azienda Ospedaliera Cannizzaro ( Site 0458)
-
Naples, Италия, 80131
- Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0462)
-
Roma, Италия, 00152
- Azienda Ospedaliera San Camillo Forlanini ( Site 0455)
-
Roma, Италия, 00168
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 0801)
-
Terni, Италия, 05100
- Azienda Ospedaliera Santa Maria Terni ( Site 0456)
-
Udine, Италия, 33100
- Az. Osp. Univ. Sta Maria della Misericordia di Udine ( Site 0460)
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Италия, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 0464)
-
Modena, Emilia-Romagna, Италия, 41124
- A.O. Universitaria di Modena ( Site 0454)
-
-
Lombardy
-
Rozzano, Lombardy, Италия, 20089
- Istituto Clinico Humanitas Research Hospital ( Site 0452)
-
-
Napoli
-
Pozzuoli, Napoli, Италия, 80078
- Presidio Ospedaliero S. Maria Delle Grazie-U.O.C. ONCOLOGIA ( Site 0802)
-
-
Pordenone
-
Aviano, Pordenone, Италия, 33081
- Centro Di Riferimento Oncologico ( Site 0800)
-
-
Veneto
-
Verona, Veneto, Италия, 37134
- Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Oncology Unit ( Site 0465)
-
-
-
-
British Columbia
-
Victoria, British Columbia, Канада, V8R 6V5
- BC Cancer Victoria-Clinical Trials Unit ( Site 0111)
-
-
Ontario
-
Greater Sudbury, Ontario, Канада, P3E 5J1
- Health Sciences North ( Site 0122)
-
Hamilton, Ontario, Канада, L8V 5C2
- Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0116)
-
Kitchener, Ontario, Канада, N2G 1G3
- Grand River Hospital ( Site 0120)
-
Oshawa, Ontario, Канада, L1G 2B9
- Lakeridge Health ( Site 0117)
-
Toronto, Ontario, Канада, M4N 3M5
- Sunnybrook Research Institute ( Site 0108)
-
Toronto, Ontario, Канада, M5G 2M9
- Princess Margaret Cancer Centre ( Site 0107)
-
-
Quebec
-
Greenfield Park, Quebec, Канада, J4V 2H1
- CISSS de la Monteregie-Centre ( Site 0119)
-
Montreal, Quebec, Канада, H2X 3E4
- Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0106)
-
Québec, Quebec, Канада, G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0103)
-
Rimouski, Quebec, Канада, G5L 5T1
- CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102)
-
Sherbrooke, Quebec, Канада, J1H 5N4
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105)
-
-
-
-
Antioquia
-
Medellín, Antioquia, Колумбия, 050034
- Hospital Pablo Tobon Uribe ( Site 1066)
-
-
Atlántico
-
Barranquilla, Atlántico, Колумбия, 080001
- Biomelab S A S ( Site 1067)
-
Barranquilla, Atlántico, Колумбия, 080020
- Clinica de la Costa S.A.S. ( Site 1073)
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Колумбия, 110311
- Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1062)
-
-
Cesar Department
-
Valledupar, Cesar Department, Колумбия, 200001
- Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1068)
-
-
Departamento de Córdoba
-
Montería, Departamento de Córdoba, Колумбия, 230002
- Oncomédica S.A.S ( Site 1057)
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Колумбия, 760042
- Clínica Imbanaco S.A.S ( Site 1064)
-
Cali, Valle del Cauca Department, Колумбия, 760042
- Hemato Oncologos S.A. ( Site 1065)
-
-
-
-
Gelderland
-
Nijmegen, Gelderland, Нидерланды, 6525 GA
- Radboud University Medical Center ( Site 0470)
-
-
Limburg
-
Maastricht, Limburg, Нидерланды, 6229 HX
- Maastricht University Medical Centre ( Site 0467)
-
-
North Brabant
-
Breda, North Brabant, Нидерланды, 4818 CK
- Amphia Hospital Location Molengracht ( Site 0474)
-
Eindhoven, North Brabant, Нидерланды, 5623 EJ
- Catharina Ziekenhuis ( Site 0472)
-
-
North Holland
-
Alkmaar, North Holland, Нидерланды, 1815 JD
- Noordwest Ziekenhuisgroep NWZ ( Site 0468)
-
Amsterdam, North Holland, Нидерланды, 1081 HV
- Vrije Universiteit Medisch Centrum ( Site 0479)
-
Hilversum, North Holland, Нидерланды, 1213 XZ
- Tergooiziekenhuizen ( Site 0466)
-
Hoofddorp, North Holland, Нидерланды, 2134TM
- Spaarne Ziekenhuis ( Site 0473)
-
-
Overijssel
-
Hengelo, Overijssel, Нидерланды, 7555 DL
- Ziekenhuisgroep Twente ( Site 0469)
-
-
South Holland
-
Leidschendam, South Holland, Нидерланды, 2501 ck
- Haaglanden MC - locatie Antoniushove ( Site 0471)
-
Schiedam, South Holland, Нидерланды, 3118 JH
- Franciscus Gasthuis en Vlietland ( Site 0489)
-
-
-
-
-
Auckland, Новая Зеландия, 1023
- Auckland City Hospital ( Site 0193)
-
-
Bay of Plenty
-
Tauranga, Bay of Plenty, Новая Зеландия, 3112
- Tauranga Hospital ( Site 0215)
-
-
Canterbury
-
Christchurch, Canterbury, Новая Зеландия, 8011
- Canterbury Regional Cancer & Blood Service ( Site 0195)
-
-
-
-
Greater Poland Voivodeship
-
Konin, Greater Poland Voivodeship, Польша, 62-500
- Przychodnia Lekarska Komed ( Site 0628)
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Польша, 85-796
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 0636)
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Польша, 02-793
- Clinical Best Solutions ( Site 0622)
-
-
West Pomeranian Voivodeship
-
Koszalin, West Pomeranian Voivodeship, Польша, 75-581
- Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0624)
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Польша, 91-211
- Salve Medica SP ( Site 0686)
-
Tomaszów Mazowiecki, Łódź Voivodeship, Польша, 97-200
- Provita Prolife Centrum Medyczne ( Site 0630)
-
-
-
-
-
San Juan, Пуэрто-Рико, 00918
- Puerto Rico Medical Research Center LLC ( Site 1122)
-
San Juan, Пуэрто-Рико, 00927
- FDI Clinical Research ( Site 1121)
-
-
-
-
Chelyabinsk Oblast
-
Chelyabinsk, Chelyabinsk Oblast, Россия, 454087
- Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565)
-
-
Krasnoyarsk Krai
-
Krasnoyarsk, Krasnoyarsk Krai, Россия, 660133
- Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0585)
-
-
Leningradskaya Oblast'
-
Gatchina, Leningradskaya Oblast', Россия, 188300
- State Budgetary Healthcare Institution "Leningrad Regional Clinical Hospital" ( Site 0588)
-
-
Moscow
-
Moscow, Moscow, Россия, 117485
- Russian Scientific Center of Roentgenoradiology ( Site 0559)
-
Moscow, Moscow, Россия, 121359
- Central Clinical Hospital with Polyclinic ( Site 0562)
-
-
Omsk Oblast
-
Omsk, Omsk Oblast, Россия, 644013
- Omsk Clinical Oncology Dispensary ( Site 0568)
-
-
Samara Oblast
-
Samara, Samara Oblast, Россия, 443031
- SBHI Samara Regional Clinical Oncology Dispensary ( Site 0576)
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, Россия, 197758
- Clinical Research Center of specialized types medical care-Oncology ( Site 0570)
-
Saint Petersburg, Sankt-Peterburg, Россия, 197758
- Russian Scientific Center of Radiology and Surgical Technologies ( Site 0567)
-
-
Tomsk Oblast
-
Tomsk, Tomsk Oblast, Россия, 634050
- Tomsk National Scientific Medical Center of Russian Academy of Science ( Site 0579)
-
-
-
-
-
Northwood, Соединенное Королевство, HA6 2RN
- Mount Vernon Cancer Centre ( Site 0536)
-
-
Bristol, City of
-
Bristol, Bristol, City of, Соединенное Королевство, BS2 8ED
- University Hospitals Bristol NHS Foundation Trust ( Site 0530)
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Соединенное Королевство, CB2 0QQ
- Cambridge University Hospitals NHS Trust ( Site 0540)
-
-
Devon
-
Torquay, Devon, Соединенное Королевство, TQ2 7AA
- Torbay Hospital ( Site 0532)
-
-
London, City of
-
London, London, City of, Соединенное Королевство, NW1 2PG
- University College London Hospitals NHS Foundation Trust ( Site 0482)
-
-
Midlothian
-
Edinburgh, Midlothian, Соединенное Королевство, EH4 2XU
- Western General Hospital ( Site 0531)
-
-
Surrey
-
London, Surrey, Соединенное Королевство, SM3 5PT
- Royal Marsden Hospital (Sutton) ( Site 0526)
-
-
Worcestershire
-
Taunton, Worcestershire, Соединенное Королевство, TA1 5DA
- Musgrove Park Hospital ( Site 0537)
-
-
-
-
Alabama
-
Mobile, Alabama, Соединенные Штаты, 36604
- University of South Alabama, Mitchell Cancer Institute ( Site 0065)
-
-
California
-
Fullerton, California, Соединенные Штаты, 92835
- Providence Medical Foundation-Oncology ( Site 0069)
-
Los Angeles, California, Соединенные Штаты, 90404
- UCLA Hematology/Oncology - Santa Monica ( Site 0081)
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- University of Colorado Cancer Center ( Site 0022)
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06513
- Smilow Cancer Hospital at Yale New Haven ( Site 0038)
-
-
Florida
-
Tampa, Florida, Соединенные Штаты, 33612
- Moffitt Cancer Center ( Site 0080)
-
-
Georgia
-
Augusta, Georgia, Соединенные Штаты, 30912
- Georgia Cancer Center at Augusta University ( Site 0026)
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60608
- Mount Sinai Hospital ( Site 0042)
-
-
Indiana
-
Merrillville, Indiana, Соединенные Штаты, 46410
- Methodist Hospitals. ( Site 0008)
-
-
Louisiana
-
New Orleans, Louisiana, Соединенные Штаты, 70112
- Tulane Cancer Center ( Site 0066)
-
-
Massachusetts
-
Worcester, Massachusetts, Соединенные Штаты, 01655
- University of Massachusetts Worcester ( Site 0053)
-
-
Michigan
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Cancer & Hematology Centers of Western Michigan ( Site 0013)
-
Traverse City, Michigan, Соединенные Штаты, 49684
- Munson Medical Center ( Site 0030)
-
-
Montana
-
Billings, Montana, Соединенные Штаты, 59102
- St. Vincent Frontier Cancer Center ( Site 0016)
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68130
- Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0034)
-
-
Nevada
-
Las Vegas, Nevada, Соединенные Штаты, 89169
- Comprehensive Cancer Centers of Nevada ( Site 0092)
-
-
New Jersey
-
Hackensack, New Jersey, Соединенные Штаты, 07601
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0004)
-
-
New York
-
Syracuse, New York, Соединенные Штаты, 13210
- Associated Medical Professionals of NY ( Site 0060)
-
-
North Carolina
-
Salisbury, North Carolina, Соединенные Штаты, 28144
- W. G. Bill Hefner VA Medical Center ( Site 0029)
-
-
Ohio
-
Canton, Ohio, Соединенные Штаты, 44718
- Gabrail Cancer Center-Research ( Site 0096)
-
Cincinnati, Ohio, Соединенные Штаты, 45212
- Tri-State Urologic Services PSC, Inc. ( Site 0094)
-
Cleveland, Ohio, Соединенные Штаты, 44106
- University Hospitals Cleveland Medical Center ( Site 0036)
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97239
- Oregon Health Science University ( Site 0031)
-
-
South Carolina
-
Myrtle Beach, South Carolina, Соединенные Штаты, 29572
- Carolina Urologic Research Center ( Site 0070)
-
-
Virginia
-
Fairfax, Virginia, Соединенные Штаты, 22031
- Inova Schar Cancer Institute ( Site 0006)
-
Richmond, Virginia, Соединенные Штаты, 23230
- Virginia Cancer Institute ( Site 0052)
-
Roanoke, Virginia, Соединенные Штаты, 24014
- Blue Ridge Cancer Care ( Site 0086)
-
-
Wisconsin
-
Milwaukee, Wisconsin, Соединенные Штаты, 53226
- Froedtert Hospital & the Medical College of Wisconsin ( Site 0045)
-
-
-
-
-
Taichung, Тайвань, 40447
- China Medical University Hospital ( Site 0132)
-
Taichung, Тайвань, 407
- Taichung Veterans General Hospital ( Site 0133)
-
Taipei, Тайвань, 10048
- National Taiwan University Hospital ( Site 0131)
-
Taipei, Тайвань, 11217
- Taipei Veterans General Hospital ( Site 0135)
-
-
Tainan
-
Tainen, Tainan, Тайвань, 704
- National Cheng Kung University Hospital ( Site 0134)
-
-
-
-
-
Adana, Турция (Туркие), 01250
- Baskent University Dr. Turgut Noyan Research and Training Center-ONCCOLOGY ( Site 0618)
-
Ankara, Турция (Туркие), 06100
- Ankara University Hospital Cebeci ( Site 0613)
-
Ankara, Турция (Туркие), 06230
- Hacettepe Universitesi-oncology hospital ( Site 0615)
-
Ankara, Турция (Туркие), 06800
- Ankara City Hospital-Medical Oncology ( Site 0616)
-
Istanbul, Турция (Туркие), 34440
- T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Baki-Istanbul Bakirkoy Sadi Konuk Training ( Site 0620)
-
Istanbul, Турция (Туркие), 34457
- Acıbadem Maslak Hastanesi ( Site 0660)
-
Istanbul, Турция (Туркие), 34722
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 0619)
-
-
İzmir
-
Bornova, İzmir, Турция (Туркие), 35100
- Ege University Medicine of Faculty ( Site 0661)
-
-
-
-
Cherkasy Oblast
-
Cherkassy, Cherkasy Oblast, Украина, 18009
- Cherkasy Regional Oncology Dispensary ( Site 1203)
-
-
Dnipropetrovsk Oblast
-
Dnipro, Dnipropetrovsk Oblast, Украина, 49005
- Dnepropetrovsk Regional Clinical Hospital Mechnikov-Department of urology ( Site 1205)
-
Dnipropetrovsk, Dnipropetrovsk Oblast, Украина, 49055
- Dnepropetrovsk Regional Clinical Oncology Hospital-Clinical oncological dispensary ( Site 1201)
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Украина, 76008
- Ivano-Frankivsk Regional Hospital-Urology department ( Site 1208)
-
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Украина, 76018
- Communal Non-Commercial Enterprise ""Prykarpatski Clinical Oncological Center"" of Ivano-Frankivsk R ( Site 1209)
-
-
Kharkiv Oblast
-
Kharkiv, Kharkiv Oblast, Украина, 61070
- CNPE Regional Center of Oncology-oncourology department ( Site 1202)
-
-
Kyivska Oblast
-
Kiev, Kyivska Oblast, Украина, 08720
- LISOD - Israeli Oncological Hospital ""MedX-ray Internationa-Department of Clinical and Scientific ( Site 1207)
-
Kyiv, Kyivska Oblast, Украина, 03115
- Municipal non-profit enterprise Kyiv City Clinical Oncology -Oncourology department ( Site 1204)
-
-
-
-
-
Paris, Франция, 75014
- Institut Mutualiste Montsouris ( Site 0446)
-
-
Aisne
-
Saint-Quentin, Aisne, Франция, 02321
- C.H. de Saint Quentin ( Site 0481)
-
-
Auvergne
-
Clermont-Ferrand, Auvergne, Франция, 63011
- Centre Jean Perrin ( Site 0434)
-
-
Bas-Rhin
-
Strasbourg, Bas-Rhin, Франция, 67000
- Clinique Sainte Anne ( Site 0431)
-
-
Brittany Region
-
Brest, Brittany Region, Франция, 29200
- CHU de Brest -Site Hopital Morvan ( Site 0441)
-
-
Doubs
-
Besançon, Doubs, Франция, 25000
- CHU Jean Minjoz ( Site 0423)
-
-
Gironde
-
Bordeaux, Gironde, Франция, 33076
- Institut Bergonie ( Site 0421)
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, Франция, 31059
- Institut Claudius Regaud IUCT Oncopole ( Site 0418)
-
-
Hauts-de-Seine
-
Suresnes, Hauts-de-Seine, Франция, 92150
- Hopital Foch ( Site 0428)
-
-
Herault
-
Montpellier, Herault, Франция, 34298
- Institut Regional du Cancer de Montpellier - ICM ( Site 0443)
-
-
Loire-Atlantique
-
Saint-Herblain, Loire-Atlantique, Франция, 44805
- Institut De Cancerologie De L Ouest ( Site 0448)
-
-
Loiret
-
Orléans, Loiret, Франция, 45100
- Centre Hospitalier Regional du Orleans ( Site 0430)
-
-
Meurthe-et-Moselle
-
Nancy, Meurthe-et-Moselle, Франция, 54000
- Centre D Oncologie de Gentilly ( Site 0432)
-
-
Nord
-
Valenciennes, Nord, Франция, 59300
- Centre Hospitalier de Valenciennes ( Site 0439)
-
-
Rhone
-
Pierre-Bénite, Rhone, Франция, 69310
- C.H.U. Lyon Sud ( Site 0436)
-
-
Somme
-
Amiens, Somme, Франция, 80000
- CHU Amiens Picardie Site Sud Amiens ( Site 0438)
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, Франция, 94800
- Institut Gustave Roussy ( Site 0416)
-
-
Vaucluse
-
Avignon, Vaucluse, Франция, 84918
- Institut Sainte Catherine ( Site 0447)
-
-
-
-
Brno-mesto
-
Brno, Brno-mesto, Чехия, 656 91
- Fakultni Nemocnice u sv. Anny v Brne-Onkologicko-chirurgicke oddeleni ( Site 1303)
-
-
Novy Jicin
-
Nový Jičín, Novy Jicin, Чехия, 741 01
- Nemocnice AGEL Novy Jicin a.s. ( Site 1304)
-
-
Olomouc Region
-
Olomouc, Olomouc Region, Чехия, 779 00
- Fakultni nemocnice Olomouc ( Site 1301)
-
-
-
-
Araucania
-
Temuco, Araucania, Чили, 4810148
- Rey y Oreilly Limitada ( Site 1048)
-
Temuco, Araucania, Чили, 4800827
- Centro Investigación del Cáncer James Lind ( Site 1041)
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Чили, 7500921
- Fundacion Arturo Lopez Perez ( Site 1049)
-
Santiago, Region M. de Santiago, Чили, 8330024
- Pontificia Universidad Catolica de Chile ( Site 1047)
-
Santiago, Region M. de Santiago, Чили, 8420383
- Bradfordhill ( Site 1044)
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Чили, 2520598
- Oncocentro ( Site 1045)
-
-
-
-
-
Seoul, Южная Корея, 03080
- Seoul National University Hospital ( Site 0171)
-
Seoul, Южная Корея, 06351
- Samsung Medical Center ( Site 0172)
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, Южная Корея, 10408
- National Cancer Center ( Site 0174)
-
Seongnam-si, Kyonggi-do, Южная Корея, 13620
- Seoul National University Bundang Hospital ( Site 0175)
-
-
Seoul
-
Songpagu, Seoul, Южная Корея, 05505
- Asan Medical Center ( Site 0176)
-
-
-
-
-
Chiba, Япония, 260-8717
- Chiba Cancer Center ( Site 0704)
-
Fukuoka, Япония, 812-8582
- Kyushu University Hospital ( Site 0718)
-
Hiroshima, Япония, 734-8530
- Hiroshima Prefectural Hospital ( Site 0748)
-
Miyazaki, Япония, 889-1692
- University of Miyazaki Hospital ( Site 0721)
-
Nagasaki, Япония, 852-8510
- Nagasaki University Hospital ( Site 0719)
-
Tokyo, Япония, 105-8470
- Toranomon Hospital ( Site 0711)
-
Tokyo, Япония, 113-8603
- Nippon Medical School Hospital ( Site 0709)
-
Tokyo, Япония, 160-8582
- Keio University Hospital ( Site 0710)
-
-
Chiba
-
Kashiwa, Chiba, Япония, 2778577
- National Cancer Center Hospital East ( Site 0702)
-
Sakura, Chiba, Япония, 285-8741
- Toho University Sakura Medical Center ( Site 0703)
-
-
Ehime
-
Matsuyama, Ehime, Япония, 791-0280
- National Hospital Organization Shikoku Cancer Center ( Site 0716)
-
-
Fukuoka
-
Iizuka, Fukuoka, Япония, 820-8505
- Iizuka Hospital ( Site 0744)
-
-
Hokkaido
-
Hakodate, Hokkaido, Япония, 040-8611
- Hakodate Goryoukaku Hospital ( Site 0739)
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Япония, 920-8641
- Kanazawa University Hospital ( Site 0701)
-
-
Kanagawa
-
Sagamihara, Kanagawa, Япония, 252-0375
- Kitasato University Hospital ( Site 0705)
-
Yokohama, Kanagawa, Япония, 232-0024
- Yokohama City University Medical Center ( Site 0706)
-
-
Miyagi
-
Natori-shi, Miyagi, Япония, 981-1293
- Miyagi Cancer Center ( Site 0747)
-
-
Nara
-
Kashihara, Nara, Япония, 634-8522
- Nara Medical University Hospital ( Site 0715)
-
-
Osaka
-
Sayama, Osaka, Япония, 589-8511
- Kindai University Hospital ( Site 0714)
-
Suita, Osaka, Япония, 565-0871
- The University of Osaka Hospital ( Site 0713)
-
-
Saitama
-
Hidaka, Saitama, Япония, 350-1298
- Saitama Medical University International Medical Center ( Site 0708)
-
Kawagoe, Saitama, Япония, 350-8550
- Saitama Medical Center ( Site 0743)
-
Koshigaya, Saitama, Япония, 343-8555
- Dokkyo Medical University Saitama Medical Center ( Site 0707)
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Япония, 431-3192
- Hamamatsu University Hospital ( Site 0720)
-
-
Yamaguchi
-
Ube, Yamaguchi, Япония, 755-8505
- Yamaguchi University Hospital ( Site 0717)
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
The main inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
- Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months prior to randomization
- Has current evidence of metastatic disease documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI)
- Has met one of the following criteria with regard to abiraterone acetate exposure: (1) is abiraterone-naïve; (2) received prior abiraterone acetate for the treatment of mHSPC or mCRPC, for a minimum of 4 weeks and not progressed while on treatment; or (3) received prior abiraterone acetate for the treatment of mHSPC or mCRPC and progressed on treatment after a minimum of 8 weeks treatment (minimum 14 weeks for those with bone progression)
- Has ongoing androgen deprivation with serum testosterone <50 ng/dL (<2.0 nM)
- Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses prior to randomization
- Participants must agree to the following during the study treatment period and for at least 90 days after the last dose of enzalutamide: Refrain from donating sperm, plus EITHER be abstinent OR must agree to use male condom
- Has provided newly obtained core or excisional biopsy (obtained within 12 months of screening) from soft tissue not previously irradiated (samples from tumors progressing in a prior site of radiation are allowed). Participants with bone only or bone predominant disease may provide a bone biopsy sample
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
Exclusion Criteria:
- Has a known additional malignancy that is progressing or has required active treatment in the last 3 years
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
- Has undergone major surgery including local prostate intervention (excluding prostate biopsy) within 28 days prior to randomization and not recovered adequately from the toxicities and/or complications
- Has a gastrointestinal disorder affecting absorption or is unable to swallow tablets/capsules
- Has an active infection (including tuberculosis) requiring systemic therapy
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
- Has known active human immunodeficiency virus (HIV), concurrent active hepatitis B virus (HBV) or known active hepatitis C virus (HCV) infection
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has hypersensitivity to pembrolizumab and/or enzalutamide and/or any of their excipients
- Has a history of seizure or any condition that may predispose to seizure
- Has a history of loss of consciousness within 12 months of screening
- Has hypotension (systolic blood pressure <86 millimeters of mercury [mmHg]) or uncontrolled hypertension (systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg) at the screening visit
- Has bradycardia (heart rate of <50 beats per minute) on the screening electrocardiogram (ECG)
- Has history of prostate cancer progression on ketoconazole
- Has had prior treatment with enzalutamide, apalutamide, darolutamide or cytochrome P450 (CYP) 17 inhibitor other than abiraterone acetate
- Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
- Has received prior treatment with radium or other therapeutic radiopharmaceuticals for prostate cancer
- Has received prior treatment with docetaxel or another chemotherapy agent for mCRPC
- Has had a prior anti-cancer monoclonal antibody (mAb) prior to randomization
- Has used herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (eg, saw palmetto) prior to randomization
- Has received a live or live attenuated vaccine within 30 days prior to randomization
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
- Has a "superscan" bone scan
- Is expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 90 days after the last dose of enzalutamide
- Has had an allogenic tissue/solid organ transplant
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Pembrolizumab + Enzalutamide
Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered orally (PO) once a day (QD) continuously until progression. |
IV infusion
Другие имена:
Capsules/Tablets
Другие имена:
|
|
Плацебо Компаратор: Placebo + Enzalutamide
Participants receive placebo by IV infusion administered on Day 1 Q3W for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered PO QD continuously until progression. |
IV infusion
Другие имена:
Capsules/Tablets
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall Survival (OS)
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
OS was defined as the time from randomization to death due to any cause. The OS for all participants is presented. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
rPFS was defined as the time from randomization to the first documented progressive disease (PD) per PCWG-modified RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurred first. The rPFS per PCWG-modified RECIST for all participants is presented. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
TFST was defined as time from randomization to initiation of the first subsequent anti-cancer therapy or death, whichever occurs first. The TFST for all participants is presented. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Prostate-specific Antigen (PSA) Response Rate
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
PSA response rate was defined as percentage of participants in the analysis population who have a negative change (decrease) in PSA level of ≥50% measured twice ≥3 weeks apart. The analysis was performed on participants who had baseline PSA measurements. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Prostate-specific Antigen (PSA) Undetectable Rate
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
PSA undetectable rate was defined as percentage of participants in the analysis population with PSA <0.2 ng/mL during study treatment. The analysis was performed on participants who had baseline PSA measurements. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Objective Response (OR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
OR was defined as the percentage of participants with complete response (CR: disappearance of all target lesions per RECIST 1.1; and no evidence of disease (NED) on bone scan per PCWG) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions per RECIST 1.1; and non-progressive disease, non-evaluable [NE], or NED on bone scan or CR with non-progressive disease or NE bone scan per PCWG). |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Duration of Response (DOR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
DOR was defined as the time from first documented evidence of complete response (CR) or partial response (PR) per PCWG and RECIST 1.1 criteria until progressive disease (PD) or death. PD per RECIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD per PCWG was the appearance of ≥2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and were persistent for ≥6 weeks. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data. If a participant had not progressed, the participant was censored at the date of last disease assessment. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Time to Prostate-specific Antigen (PSA) Progression
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
Time from randomization to PSA progression. PSA progression date is defined as the date of 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, or 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
Time from randomization to radiographic soft tissue progression per PCWG-modified RECIST 1.1 |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and Opiate Analgesic Use (Analgesic Quantification Algorithm [AQA] Score)
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
Time from randomization to pain progression. In this study, pain progression was assessed by participant responses to Item 3 of the BPI-SF and participant AQA Scores which are both assessed by participants daily for 7 consecutive days. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Time to First Symptomatic Skeletal-related Event (SSRE)
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
Time from randomization to the first SSRE. SSRE is defined as radiation to prevent or relieve skeletal symptoms, occurrence of new symptomatic pathological fracture, spinal cord compression, or surgery to bone. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Number of Participants Who Experience an Adverse Event (AE)
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. The number of participants who experienced an AE is presented. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
|
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
Временное ограничение: Up to 40 months (through database cut-off date of 12-Dec-2022)
|
An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. The number of participants who discontinued study treatment due to an AE is presented. |
Up to 40 months (through database cut-off date of 12-Dec-2022)
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Medical Director, Merck Sharp & Dohme LLC
Публикации и полезные ссылки
Общие публикации
- Graff JN, Liang LW, Kim J, Stenzl A. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Future Oncol. 2021 Aug;17(23):3017-3026. doi: 10.2217/fon-2020-1008. Epub 2021 May 28.
- Graff JN, Burotto M, Fong PC, Pook DW, Zurawski B, Manneh Kopp R, Salinas J, Bylow KA, Kramer G, Ratta R, Kwiatkowski M, Retz M, Kwak C, Arranz Arija JA, Gurney H, Matsubara N, Villanueva L, Todenhofer T, Liang LW, Todoric J, Imai K, Stenzl A; KEYNOTE-641 Investigators. Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study. Ann Oncol. 2025 Aug;36(8):976-987. doi: 10.1016/j.annonc.2025.05.007. Epub 2025 May 16.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Генитальные заболевания
- Генитальные новообразования, мужчины
- Урогенитальные новообразования
- Новообразования по локализации
- Новообразования
- Заболевания половых органов, мужчины
- Заболевания предстательной железы
- Мужские мочеполовые заболевания
- Новообразования предстательной железы
- Болезнь Паркинсона 4, аутосомно -доминантное тело Льюи
- Фармацевтические препараты
- Кристаллоидные решения
- Изотонические решения
- Решения
- Солевой раствор
- Пембролизумаб
- энзалутамид
Другие идентификационные номера исследования
- 3475-641
- 2018 (Грант/контракт NIH США)
- MK-3475-641 (Другой идентификатор: Merck Protocol Number)
- KEYNOTE-641 (Другой идентификатор: Merck)
- 195005 (Идентификатор реестра: JAPIC-CTI)
- 2022-500785-10-00 (Идентификатор реестра: EU CT)
- 2018-004117-40 (Номер EudraCT)
- U1111-1278-1151 (Идентификатор реестра: UTN)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .